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Neuronal excitation can be substantially modulated
by alterations in metabolism, as evident from the
anticonvulsant effect of diets that reduce glucose
utilization and promote ketone body metabolism.
We provide genetic evidence that BAD, a protein
with dual functions in apoptosis and glucose metab-
olism, imparts reciprocal effects on metabolism of
glucose and ketone bodies in brain cells. These
effects involve phosphoregulation of BAD and are
independent of its apoptotic function. BADmodifica-
tions that reduce glucose metabolism produce
a marked increase in the activity of metabolically
sensitive KATP channels in neurons, as well as resis-
tance to behavioral and electrographic seizures
in vivo. Seizure resistance is reversed by genetic
ablation of the KATP channel, implicating the BAD-
KATP axis in metabolic control of neuronal excitation
and seizure responses.INTRODUCTION
Neuronal electrical activity is tightly integrated with mitochon-
drial nutrient and energy metabolism in the brain. In addition to
buffering intracellular calcium and generating ATP for proper
maintenance of ion homeostasis, mitochondria can influence
neuronal function by changing redox balance and availability of
intermediary metabolites for biosynthetic processes (MacAskill
et al., 2010; Nicholls, 2009). Although glucose is the predominant
mitochondrial fuel utilized by the brain, neural cells can metabo-
lize alternative carbon substrates, such as ketone bodies, under
conditions of glucose limitation or dietary restrictions (Zielke
et al., 2009). The capacity of mitochondria to process alternate
energy substrates, such as carbohydrates and ketone bodies,
may influence neuronal excitability. For example, the ketogenic
diet (KD), which reduces glucose metabolism and promotes
the breakdown of fatty acids to generate ketone bodies, hasshown efficacy in many cases of pharmacoresistant epilepsy
(Hartman et al., 2007; Neal et al., 2009; Thiele, 2003).
The potent effect of increased ketone body metabolism on
epilepsy in humans points to a link between mitochondrial fuel
utilization and neuronal excitability. However, the molecular
underpinnings of this link are not fully understood. Numerous
mechanisms have been proposed (Schwartzkroin, 1999),
including alterations in gene expression (Garriga-Canut et al.,
2006) and changes in the levels of metabolic products and
byproducts, such as ATP (DeVivo et al., 1978), amino acids
(Dahlin et al., 2005; Yudkoff et al., 2001), reactive oxygen
species, and glutathione (Jarrett et al., 2008). Moreover, ketone
bodies can alter the open probability of themetabolically respon-
sive ATP-sensitive potassium (KATP) channels (Ma et al., 2007;
Schwartzkroin, 1999; Tanner et al., 2011). This can lead to
reduced firing of neurons and reduced excitability during
seizures. Ketone bodies have also been reported to suppress
the vesicular release of glutamate, suggesting a link between
metabolism and excitatory synaptic transmission (Juge et al.,
2010). Other proposed mechanisms for the anticonvulsant effect
of KD include elevation of inhibitory neurotransmitter g-amino-
butyric acid (GABA) levels (Wang et al., 2003; Yudkoff et al.,
2001), acidosis-induced changes in acid-sensing ion channel
1a (ASIC1a; Ziemann et al., 2008), and changes in the activity
of A1 purinergic receptors (Masino et al., 2011).
Although these mechanisms have provided valuable insights
into metabolic regulation of seizure responses, progress in dis-
secting the link between metabolism and seizure sensitivity
has been difficult because of the complex systemic effects of
dietary alterations and the relatively modest effect of KD in
rodent models of epilepsy. Identification of cell-intrinsic mecha-
nisms and molecular modulators that can simultaneously atten-
uate glucose metabolism and enhance ketone body consump-
tion without any dietary manipulation may provide a useful
molecular handle on understanding the metabolic control of
seizure sensitivity.
BAD (BCL-2-associated Agonist of Cell Death) is a member of
the BCL-2 family of cell death/survival proteins (Chipuk et al.,
2010; Danial and Korsmeyer, 2004; Youle and Strasser, 2008).
Separate from its well-established role in apoptosis, BAD
modulates glucose metabolism in multiple cell types, includingNeuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc. 719
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Figure 1. Blunted Mitochondrial Metabo-
lism of Glucose in Primary Bad–/– and
BadS155A Neurons and Astrocytes
(A) Representative trace of oxygen consumption
rate (OCR) measured in real-time indicating basal
and maximal respiration rates (BR and MR,
respectively).
(B and C) BR and MR in the presence of glucose
in primary Bad/ cortical neurons (B) and astro-
cytes (C).
(D and E) BR and MR in the presence of glucose in
primary BadS155A cortical neurons (D) and astro-
cytes (E). Data in (B) through (E) are presented as
mean ± SEM; n = 4–6 independent neuron or
astrocyte cultures. *p < 0.05; **p < 0.01; ***p <
0.001; wild-type versus Bad/ or BadS155A; two-
tailed Student’s t test.
See also Figure S1.
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Metabolic Control by BAD Reduces Seizures via KATPhepatocytes, islet b cells, and fibroblasts (reviewed in Danial,
2008). BAD’s dual modalities in apoptosis and metabolism
are mediated through a phosphoregulatory mechanism that
modifies serine 155 (aa enumeration based on the murine
sequence of BAD) located within an alpha helical segment
known as the BCL-2 homology (BH)-3 domain (Danial et al.,
2008; Datta et al., 2000). In hepatocytes and b cells, serine 155
phosphorylation is required for mitochondrial metabolism of
glucose (reviewed in Danial, 2008). In the presence of apoptotic
signals, including irreversible cellular damage, dephosphory-
lated BAD engages the mitochondrial apoptosis machinery
through a BH3 domain-dependent mechanism that sensitizes
cells to apoptosis.
Reduced glucose metabolism associated with BAD modifica-
tion is reminiscent of reduced glycolysis and changes in carbon
substrate utilization in response to a low carbohydrate diet that
promotes ketone body metabolism. This prompted us to inves-
tigate potential BAD-dependent changes in seizure responses.720 Neuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc.Using a combination of genetic models,
mitochondrial respirometry, and electro-
physiology, as well as electrographic
and behavioral studies, we have exam-
ined the role of BAD in regulating the pre-
ferred carbon substrate utilized by neural
cell types and its relevance to neuronal
excitability and seizure sensitivity.
RESULTS
Blunted Mitochondrial Metabolism
of Glucose in Primary Bad–/– and
BadS155A Neurons and Astrocytes
Our previous findings—that BAD is
required for mitochondrial utilization of
glucose in hepatocytes and islet b cells
(Danial et al., 2003, 2008)—prompted us
to examine how BAD modification may
affect glucose metabolism in the brain,
where glucose is the predominant carbonand energy substrate. We assessed mitochondrial metabolism
of glucose in primary cultures of cortical neurons and astrocytes
(Figure S1 available online) by real-time measurement of mito-
chondrial oxygen consumption rates (OCR). We focused
predominantly on two respiratory parameters; glucose-associ-
ated basal (steady-state) and maximal respiratory rates (BR
and MR, Figure 1A). Mitochondrial MR is an important indicator
of a cell’s bioenergetic fitness for accommodating any potential
rise in metabolic demand (Brand and Nicholls, 2011; Fern, 2003).
MR is defined by the fraction of maximal achievable rate of
oxygen consumption that is sensitive to the inhibition of mito-
chondrial respiratory chain activity. To measure MR, neural
cultures were first treated with the proton ionophore FCCP to
induce maximal OCR prior to treatment with the mitochondrial
respiratory chain inhibitor rotenone, and the difference between
respiratory rates in response to FCCP and rotenone was
measured (Brand and Nicholls, 2011; Figure 1A). When supplied
with glucose, neurons and astrocytes derived from Bad/mice
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Figure 2. Mitochondrial Metabolism of Non-
glucose Fuels in Bad–/– and BadS155A
Neurons and Astrocytes
(A and B) Mitochondrial maximal respiration (MR)
in wild-type and Bad/ neurons (A) and astro-
cytes (B) supplied with 5 mM L-glutamine or 5 mM
L-lactate.
(C and D) MR in the presence of 5 mM b-D-
hydroxybutyrate in primary neurons (C) and
astrocytes (D) derived from Bad/ and BadS155A
mice. Data in (A) through (D) are presented as
mean ± SEM; n = 4–6 independent neuron or
astrocyte cultures. *p < 0.05; **p < 0.01; ***p <
0.001; n.s. in (A) and (B), nonsignificant; wild-type
versus Bad/ or BadS155A; two-tailed Student’s
t test.
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Metabolic Control by BAD Reduces Seizures via KATPdisplayed diminished basal OCR and MR compared with wild-
type counterparts (Figures 1B and 1C), providing genetic
evidence for BAD’s relevance in mitochondrial handling of
glucose in these cell types.
We have previously shown that phosphorylation of BAD on Ser
155 within its BH3 domain mediates its effect on glucose metab-
olism (Danial et al., 2008). Consistent with this idea, we found
that in primary neurons and astrocytes frommice bearing a non-
phosphorylatable knockin allele of BAD (BadS155A), glucose-
associated BR and MR were significantly blunted, analogous
to Bad/ cells (Figures 1D and 1E). Importantly, as the Bad
null and S155A alleles have opposite effects on apoptosis (Danial
et al., 2008), the comparable diminution of glucose-associated
MR in neural cell types derived from both genetic models
suggests that modulation of mitochondrial fuel handling stems
from metabolic modulation by BAD rather than its effect on
apoptosis.
BAD-Dependent Increase in Ketone Body Consumption
in the Face of Diminished Glucose Oxidation
Diminished mitochondrial oxidation of glucose warranted inves-
tigation whether BAD modification alters consumption of non-
glucose fuels in neurons and astrocytes. To test this possibility,
we focused on three main physiologic nonglucose carbon
substrates that can be utilized by the brain, namely, L-glutamine,
L-lactate, and the ketone body b-D-hydroxybutyrate (Zielke
et al., 2009). We used mitochondrial MR as an indicator of mito-
chondrial fuel handling in response to each of these nonglucose
fuels.
Bad ablation did not alter mitochondrial handling of carbon
substrates, such as L-lactate and L-glutamine, in neurons or
astrocytes (Figures 2A and 2B). On the other hand, mitochondrialNeuron 74, 719–utilization of b-D-hydroxybutyrate was
significantly higher in Bad/ cortical
neurons and astrocytes compared with
wild-type cells (Figures 2C and 2D), indi-
cating that Bad ablation is associated
with a selective switch in fuel preference
from glucose to ketone body consump-
tion rather than pleiotropic changes in
mitochondrial carbon substrate utiliza-tion. In addition, a preferential shift to ketone body consumption
was observed in cortical neurons and astrocytes derived from
BadS155A mice (Figures 2C and 2D), suggesting that BAD phos-
phorylation on S155 may normally inhibit ketone body utilization.
Taken together, these observations are consistent with a BAD-
dependent reciprocal programming of mitochondrial glucose
versus ketone body consumption that is regulated by the phos-
phorylation status of its BH3 domain.
Altered Sensitivity of Bad–/– and BadS155A Mice
to Behavioral Seizures
Metabolic manipulations, such as a high-fat, low-carbohydrate
ketogenic diet (KD), can prevent seizures in many cases of phar-
macoresistant human epilepsy, as well as in certain rodent
models of epilepsy (Stafstrom and Rho, 2004). The reprogram-
ming of carbon substrate metabolism in Bad/ and BadS155A
neurons and astrocytes is analogous to ketogenic-diet-induced
changes in brain metabolism, namely, reduced glucose metab-
olism and elevated ketone body consumption. However, these
BAD-dependent changes occur in the absence of any dietary
manipulations. This led us to hypothesize that metabolic control
by BAD may also influence seizure sensitivity in vivo, similar to
the KD (Stafstrom and Rho, 2004). To test this hypothesis, we
used the chemical proconvulsant kainic acid (KA), which induces
acute seizures by stimulating excitatory glutamate receptors
(Ben-Ari et al., 1980). Published studies in mice indicate that
KD can delay the onset of KA-induced seizures (Jeong et al.,
2011; Noh et al., 2003). The seizure responses in BAD mutant
and control mice treated with KA were scored using a modified
Racine scale as previously described (Ferraro et al., 1997).
Wild-type mice experienced an acute, yet transient, series of
seizures that peaked on average between 50–120 min after KA730, May 24, 2012 ª2012 Elsevier Inc. 721
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Figure 3. Resistance of Bad Genetic Models to
Kainic-Acid- andPentylenetetrazole-InducedAcute
Seizures
(A and B) Raw seizure scores in 8- to 10-week-old male
Bad/ (A) andBadS155A (B) mice compared with wild-type
control animals over a 4 hr period after a single i.p. injec-
tion of kainic acid (KA) at 30 mg/kg. See also Figure S2.
(C) Integrated seizure severity of the above experimental
cohorts and Bid/ mice similarly treated with KA. The
scoring scale and the formula used to derive seizure
severity are provided. Wild-type, n = 42; Bad/, n = 13;
BadS155A, n = 20; Bid/; n = 9.
(D) Integrated seizure severity in Bad/ and wild-type
mice (n = 16) subjected to a single s.c. injection of penty-
lenetetrazole (PTZ) at 80 mg/kg monitored over a 70 min
period. Data in (A) through (D) are presented as mean ±
SEM. ***p < 0.001; n.s., nonsignificant; two-tailed
Student’s t test.
See also Figures S3, S4, and S5.
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Metabolic Control by BAD Reduces Seizures via KATPadministration and then slowly decayed (Figures 3A and 3B). The
seizure diaries for individual mice are shown in Figure S2. The
majority of wild-type mice (>80%) underwent status epilepticus
with very severe tonic-clonic seizures. In striking contrast,
Bad/ mice did not progress in severity to the extent of wild-
type animals and were significantly protected from status
epilepticus (Figure 3A). BadS155A mice were similarly resistant
to behavioral seizures in this experimental model (Figure 3B).
In addition to raw seizure scores based on the modified Racine
scale, we integrated individual scores per mouse over the dura-
tion of the experiment to better account for seizure severity in
mice that died during the experiment (Figure 3C). Seizure
severity was significantly diminished in both Bad null and
S155A knockin mice (Figure 3C). Moreover, seizure resistance
in the absence of BAD is not limited to the kainate model.
Bad null mice were also protected against status epilepticus722 Neuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc.triggered by pentylenetetrazole (PTZ), which
antagonizes GABAergic inhibitory receptors
(Bough and Eagles, 1999; Ferraro et al., 1999;
Figure 3D).
To determine whether seizure resistance in
Bad/ and BadS155A mice is accompanied by
neurobehavioral abnormalities, we conducted
a detailed battery of cognitive and motor func-
tion tests. These studies did not reveal any
significant differences in Bad genetic models
compared with control mice (Figure S3). It there-
fore appears unlikely that thesemodels produce
major circuit-level effects that impair normal
brain function and might also disrupt seizure
mechanisms.
As the Bad null and S155A alleles have oppo-
site effects on BAD’s apoptotic function (Danial,
2008), the comparable resistance to seizures
observed in Bad null and S155A mice cannot
be explained by changes in apoptosis. To
further test for the specificity and selectivity of
BAD in this paradigm, BID-deficient mice wereexamined. BID (BH3-Interacting domain Death agonist) is
another BH3-only proapoptotic member of the BCL-2 family
similar to BAD but does not affect glucose metabolism (Danial,
2008). Bid null mice displayed comparable sensitivity to seizures
as was seen in wild-type littermates (Figure 3C). In addition,
targeted deletion of another BH3-only proapoptotic molecule
BIM (BCL2-Interacting Mediator of cell death) in the brain did
not confer resistance against acute seizures (Figure S4). Thus,
it appears that the seizure-resistance phenotype of BAD mutant
mice is neither related to BAD’s apoptotic role nor universally
shared among other BCL-2 family members.
Changes in the preferential ability to utilize ketone bodies in
the absence of BAD and the attendant resistance to acute
seizures may derive from local metabolic alterations in the
brain and/or from altered metabolism in the liver, which is the
body’s main source of ketone body production. Two lines of
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A B Figure 4. EEGs of Kainic-Acid-Induced
Seizure Activity in Wild-Type and Bad–/–
Animals
(A) A single representative EEG channel recording
of approximately 1 hr for each genotype (right
frontoparietal electrode). A single i.p. injection of
kainic acid (30 mg/kg of body weight) was
administered at the indicated time. The green
block arrow near the end of the wild-type
recording indicates the time of death during
generalized tonic-clonic status epilepticus.
(B) The average fraction of time spent in a high-
energy spiking period for each genotype during
a 30 min period beginning 3 min after injection.
EEGs were scored by an investigator blind to the
genotype, guided by both the raw EEG traces and
a trace of power in the 20–70 Hz band to identify
onset and offset of high-energy spiking (typically
seen as rapid increases or decreases ofR5 dB in
power). Wild-type, n = 17; Bad/, n = 20; mean ±
SEM, *p < 0.05 by two-tailed Student’s t test. In
these cohorts, 9 of 17 wild-type and 0 of 20Bad/
animals died during status epilepticus.
See also Figure S3.
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Metabolic Control by BAD Reduces Seizures via KATPinvestigation suggest that seizure protection in the absence of
BAD cannot be explained by systemic alterations in ketone
body metabolism. First, we have not observed any differences
in the serum levels of ketone bodies in these animals (data not
shown). Second, liver-specific knockdown of Bad does not
produce seizure protection in mice (Figure S5), despite fully
mimicking the hepatic phenotype of Bad/ mice (data not
shown). These results are especially relevant as liver is the chief
source of ketone bodies for systemic supply to other tissues. Our
observations suggest that local metabolic alterations in the brain
of Bad/ animals, rather than systemic changes in ketone body
metabolism, most likely contribute to seizure protection in the
absence of BAD.
Altered Electrographic Seizures in Bad–/– Mice
Seizures produced by kainic acid, as for several other convulsant
treatments in rodents, appear first as hypoactivity and focal
‘‘limbic seizures’’ involving automatisms, facial and forelimb
clonus, and rearing; these seizures can progress to generalized
tonic-clonic seizures and death (Velı´skova´, 2005). The former are
attributed to forebrain or limbic activity, whereas the generalized
seizures are thought to be mediated by brainstem or midbrain
reticular systems (Browning, 1994). In several rodent seizure
models that follow this pattern, clinically useful anticonvulsants,
such as phenytoin (Browning et al., 1990), levetiracetam (Klit-
gaard et al., 1998), and topiramate (Haugvicova´ et al., 2000),
have little effect on the focal seizures but disrupt progression
to generalized motor seizures.
A similar protection against generalized seizures in the intra-
peritoneal (i.p.) kainate model was seen in the behavioral
experiments on mice with alteration of BAD. Bad/ mice or
BadS155A knockin mice rarely exhibited generalized motor
seizures (and when they occurred they were very brief), whereas
most control animals had severe generalized seizures, and
many control animals died during status epilepticus (Figures 3
and S2).In addition to noting this marked difference in behavioral
seizure response, we performed video-electroencephalographic
(EEG) analysis of the behavioral and electrographic seizures in
cohorts of wild-type and Bad/ mice subjected to i.p. kainate
injection (Figure 4). As expected from the hypothesized deep-
brain localization of the generalized motor seizures, the frontal
and parietal screw electrodes did not report a clear electro-
graphic correlate to the more severe seizures. They did,
however, record high amplitude spiking activity that was usually
correlated with the limbic seizures—as the electrographic
activity intensified, a typical progression was seen from head
movement to rearing with unilateral or bilateral forelimb clonus,
which ceased upon the usually sudden cessation of spiking.
Overall comparison of electrographic activity was complicated
by the death of wild-type animals, often seen 30 min after KA
injection in this cohort; we therefore restricted the analysis to
the first 30 min after injection. For the Bad/ mice, the fraction
of time spent in a spiking state was significantly reduced
compared to the wild-type mice (Figure 4B), indicating a reduc-
tion in forebrain seizure activity in addition to the marked reduc-
tion in generalized seizures and death during status epilepticus.
BAD Manipulation Increases KATP Channel Activity
ATP-sensitive K+ (KATP) channels are a well-known link between
metabolism and cellular electrical activity. They are octamers
comprised of four pore-forming Kir6.2 subunits and four
modulatory SUR subunits and are inhibited by intracellular ATP
(Nichols, 2006; Proks and Ashcroft, 2009; Yellen, 2008). These
channels are expressed in many brain regions associated with
epileptiform activity, such as the hippocampus (Dunn-Meynell
et al., 1998; Karschin et al., 1997; Zawar et al., 1999). Addition-
ally, KATP channel activity is increased when ketone bodies are
applied to central neurons (Ma et al., 2007; Tanner et al., 2011).
To investigate a possible role of the KATP channel in mediating
the seizure resistance of Badmutant mice, we performed patch-
clamp recordings in the cell-attached configuration from dentateNeuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc. 723
A B
C D E
Figure 5. BAD Manipulations Increase KATP Channel Activity in Dentate Granule Neurons
(A) Continuous recordings of wild-type (left) or Bad/ (right) single-channel currents in cell-attached patches with zero applied voltage. Single-channel openings
are seen as downward deflections of the current trace.
(B) N$Popen values for WT and Bad
/ single channel recordings. For the Bad/ recordings, the KATP blocker tolbutamide was added (Tolb; 200 mM) and then
washed out (Washout). n = 6 for each genotype.
(C) Maximum activatable KATP conductance determined from the difference between the slope conductance at the time of break-in and after conductance run-up
(Gmax), with low ATP (0.3 mM) in the recording pipette, for the indicated genotypes and for WT in the presence of 200 mM tolbutamide (WT + Tolb).
(D) ‘‘Washdown’’ of an initially high KATP conductance, with high ATP (4 mM) in the recording pipette, seen in Bad
/ and Bad S155A but not in WT or in Bad/;
Kir6.2/. The time course of slope conductance measured during whole-cell recording was normalized to the value 3 min after break-in.
(E) ‘‘Washdown’’ (measured as in D) prevented by preincubation in 200 mM tolbutamide. Data in (B) through (E) are presented as mean ± SEM.
See also Figure S6.
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Metabolic Control by BAD Reduces Seizures via KATPgranule neurons (DGNs) in hippocampal slices, under recording
conditions that block activity from most other channels (Tanner
et al., 2011). The open probability (Popen) of single KATP channels
was substantially increased in BAD-deficient neurons (Figures
5A and 5B). The highly active single channels measured in
Bad/ neurons were reversibly inhibited in the presence of
200 mM tolbutamide, a KATP channel inhibitor, thus confirming
their identity (Figure 5B). These results indicate that, at the single
channel level, the Popen of KATP channels is increased in Bad null
mice.
We also tested the effect of BAD alteration on the total number
of functional channels present in the cell membrane by
measuring whole-cell KATP currents in DGNs. To measure the
total activatable KATP conductance, we performed whole-cell
recordings with reduced ATP (0.3 mM) in the pipette solution;
in such experiments, KATP channels are disinhibited as the
cellular contents exchange with the pipette. In wild-type, Bad/
or BadS155A neurons, the cellular slope conductance increased
to a maximum total activatable (‘‘run-up’’) value within 10 min
(Figure 5C) and the values were very similar for these three geno-724 Neuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc.types. As expected for a KATP-mediated current, current
‘‘run-up’’ was absent in Kir6.2/ neurons or in wild-type
neurons that were incubated in 200 mM tolbutamide prior to
recording (Figure 5C).
To test for a whole-cell correlate of the high resting single
channel Popen observed in cell-attached patches, we performed
experiments with high ATP (4 mM) in the pipette, with the idea
that as the ATP washes into the cell it might inhibit any initially
active KATP channels. Indeed, we found that conductance in
Bad/ neurons decreased within the first minute after break-in
with high ATP and then remained constant (Figure 5D). This
‘‘washdown’’ was not seen in wild-type cells (Figure 5D). It
was also eliminated in Bad/ neurons if they were preincubated
with tolbutamide (Figure 5E) or in neurons from animals
that lacked both BAD and Kir6.2 (Figure 5D), confirming
that this initial high conductance was due to KATP channels.
Current washdown also occurred in neurons from BadS155A
mice (Figure 5D), showing that it is BAD’s metabolic, rather
than apoptotic, function that is responsible for increasing KATP
conductance.
01
2
3
4
S
e
iz
u
re
 S
e
v
e
ri
ty
 (
R
a
c
in
e
 S
c
a
le
) 
0 25 50 75 100 125 150 175 200 225 250
Wild-type  (n=42)
Bad -/-  (n=16)
Bad -/-;Kir6.2 -/-  (n=15)
Kir6.2 -/-  (n=23)
0
20
40
60
100
80
120 ***
n.s.
WT Bad -/-
S
e
iz
u
re
 S
e
v
e
ri
ty
 (
%
)
Bad -/-;
Kir6.2 -/-
Kir6.2 -/-
**
A
B
***
Time (min)
Figure 6. BAD Modulation of Seizure Resistance Is Dependent on
the KATP Channel
(A and B) Raw scores (A) and seizure severity (B) inBad/ and Kir6.2/ single
mutants and Bad/; Kir6.2/ double mutant mice compared with wild-type
mice after a single i.p. injection of kainic acid monitored and analyzed as in
Figure 3. Data are presented as mean ± SEM. **p < 0.01; ***p < 0.001; n.s.,
nonsignificant; two-tailed Student’s t test.
See also Figure S6.
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on the KATP Channel
The marked increase in KATP channel open probability in Bad
/
DGNs suggests a link between KATP channel conductance and
seizure protection in these mice and predicts that BAD’s effect
on seizure sensitivity may be mediated by the KATP channel. To
test this prediction, we generated Bad/; Kir6.2/ double
mutant mice and tested their sensitivity to KA in parallel with
singleBad/ or Kir6.2/mutants. Ablation of the Kir6.2 subunit
in the Bad null genetic background substantially diminished the
seizure resistance phenotype of Bad/ mice (Figures 6A and
6B). Single deletion of the Kir6.2 subunit did not sensitize mice
to acute seizures, arguing against an orthogonal or additive
effect on seizures. These findings provide genetic evidence
that the KATP channel is required for mediating BAD’s effect on
neuronal excitability.
DISCUSSION
Using a combination of genetic models and multiple experi-
mental approaches ranging from mitochondrial respirometry inprimary neural cultures and slice electrophysiology to behavioral
and electrographic seizure monitoring in vivo, we provide
a vertical analysis of BAD’s effect on neural carbon substrate
utilization, neuronal excitability, and seizure susceptibility. Our
observations suggest that BAD imparts reciprocal effects on
glucose and ketone body consumption through a phosphoregu-
latory mechanism that modifies S155 within its BH3 domain.
Specifically, BADdeficiency or interferencewith its phosphoryla-
tion is associated with diminished mitochondrial metabolism of
glucose and a concomitant metabolic preference for ketone
bodies. An electrophysiologic consequence of this metabolic
shift is a marked increase in the open probability of the metabol-
ically sensitive KATP channel. Moreover, genetic studies indicate
that this link between BAD-dependent programming of neural
metabolism and neuronal excitability extends to reductions in
electrographic and behavioral seizures, including the near
absence of generalized tonic-clonic seizures. Importantly,
BAD-dependent changes in seizure sensitivity are reversed by
genetic modification of the Kir6.2 pore-forming subunit of the
KATP channel, indicating that the KATP channel is a necessary
downstream mediator of BAD’s effect on neuronal excitation
and seizure responses.
Several lines of evidence indicate that BAD modulation of
sensitivity to acute seizures is distinct from alterations in the
apoptotic pathway or a mere change in neuronal populations
that might be expected from modification of a proapoptotic
molecule. We have not found any evidence of neuronal loss in
wild-type mice or Bad genetic models within the time course of
acute seizures induced by i.p. delivery of KA (data not shown).
Importantly, the shared seizure phenotype of Bad null and Bad
S155A alleles that otherwise have opposite effects on BAD’s
apoptotic activity is consistent with the predominance of
BAD’s nonapoptotic properties in this setting. However, our find-
ings do not argue against a role for apoptosis in epileptogenesis
(Engel et al., 2011). Indeed, our experimental system of acute
seizures is distinct from a chronic model of seizures induced
by hippocampal damage 1–12 days after stereotactic delivery
of KA in the amygdala (Engel et al., 2010; Murphy et al., 2010).
In this model, loss of certain proapoptotic members of the
BCL-2 family, such as BIM and PUMA, is protective against
neuronal loss and brain damage associated with status epilepti-
cus. However, ablation of Bim or Puma did not protect against
acute seizures immediately after KA administration (Engel
et al., 2010; Murphy et al., 2010). These observations are in
agreement with our results that tissue-specific deletion of Bim
in the brain does not alter the sensitivity to acute seizures
(Figure S4).
Our findings are also distinct from previous reports sug-
gesting a role for BAD in regulating synaptic transmission
through modified recruitment/activation of proteins with known
function in the regulation of the core apoptotic machinery,
such as BAX, caspase-3, BCL-XL, and VDAC (Hickman et al.,
2008; Jiao and Li, 2011). Based on these studies, Bad null and
BadS155A nonphosphorylatable mutants are predicted to
exert opposite effects on the activity of these proteins. This is
different from the shared phenotype of these BAD modifications
in the neuronal activity we report here. Our results are instead
consistent with involvement of BAD-dependent changes inNeuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc. 725
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machinery.
Metabolic changes similar to those produced by BAD manip-
ulation have been found effective against epileptic seizures,
notably, in the case of therapeutic diets, such as the KD.
Reduced carbohydrate diets, such as the KD (Hartman et al.,
2007; Neal et al., 2009; Thiele, 2003) and the low glycemic index
treatment (Pfeifer et al., 2008; Pfeifer and Thiele, 2005), are effec-
tive against human epileptic seizures that are refractory to anti-
convulsant drugs. These diets mimic fasting by reducing the
carbohydrate supply and forcing the breakdown of fatty acids
and utilization of ketone bodies as predominant carbon
substrates. Whether it is reduced glucose metabolism per se,
increased ketone body metabolism, or a combination of both
that mediates seizure protection is under active investigation.
However, this metabolic shift clearly reduces the incidence of
seizures. In experimental animals, glycolytic inhibition can alter
gene regulation and reduce epileptogenesis in a kindling model
(Garriga-Canut et al., 2006; Stafstrom et al., 2009).
The reduced capacity to metabolize glucose and a simulta-
neous increase in the propensity to metabolize ketone bodies
upon BAD modification is consistent with fuel competition (Hue
and Taegtmeyer, 2009) and recapitulates the actual change in
fuel consumption by the brain in fasting (Owen et al., 1967) or
on KD (DeVivo et al., 1978). However, these BAD-dependent
changes occur in the absence of dietary manipulation.
Compared with systemic effects of dietary alterations, the
seizure resistance in Bad null and S155A mice appears to likely
arise from alterations in brain cell metabolism rather than
systemic changes. In support of this idea, liver knockdown of
Bad is not sufficient to produce seizure resistance (Figure S5)
while it mimics the metabolic phenotype of the Bad null allele
in the liver (data not shown). In addition, serum levels of circu-
lating ketone bodies are not elevated in BAD-deficient mice
under steady-state conditions (data not shown), thus it seems
unlikely that changes in brain metabolism are driven by systemic
changes.
The BAD-dependent metabolic shift can be demonstrated at
the cellular level with changes in carbon substrate consumption
in primary neuron or astrocyte cultures, consistent with cell-
autonomous metabolic effects of BAD. These metabolic
changes have the consequence of elevating the open probability
of KATP channels, as seen in both whole-cell and cell-attached
recordings from DGNs in brain slices. Either glucose deprivation
or ketone body metabolism can produce elevated KATP channel
activity, and these effects can be augmented by increased
neuronal firing (Ma et al., 2007; Tanner et al., 2011), as seen
during seizures. The exact mechanism of KATP channel activa-
tion by BAD-dependent metabolic changes is not known;
changes in ATP and ADP are a possible mechanism, though
other metabolites, such as PIP2, are also known to regulate the
activity of KATP channels (Nichols, 2006), and we cannot rule
out changes in the properties of the channel through some
unknown signal resulting from genetic alteration of Bad. Total
cellular ATP levels and the ATP/ADP ratio in whole brain under
steady-state conditions are comparable in WT and Bad/
brains (Figures S6A and S6B). However, these measurements
may not reflect the dynamic fluctuations that occur during726 Neuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc.seizures or local changes that could contribute to the increased
activity of the KATP channel. Remarkably, the whole brain content
of b-hydroxybutyrate is significantly higher in Bad/ mice
compared with controls (Figure S6C). As ketone bodies can
increase the activity of the KATP channel in central neurons (Ma
et al., 2007; Tanner et al., 2011), their higher content in Bad/
brain may provide, at least in part, a link to the observed increase
in KATP channel activity. Interestingly, although the whole brain
content of ketone bodies in Bad/ mice is elevated, the serum
level of these metabolites are unaltered (data not shown), sug-
gesting local changes in ketone body generation and handling.
The observed increase in KATP activity in dentate granule
neurons indicates one way in which BAD induced metabolic
changes might lead to seizure resistance. The dentate gyrus,
where DGNs are located, has been hypothesized to be one of
the regions of the brain capable of functioning as a ‘‘seizure
gate’’ (Brenner et al., 2005; Coulter, 1999; Heinemann et al.,
1992; Hsu, 2007). However, these neurons are only one of the
many types of central neurons that express KATP channels
(Dunn-Meynell et al., 1998; Inagaki et al., 1996; Karschin et al.,
1997; Zawar et al., 1999), and important effects may also arise
elsewhere.
In addition to the observation that KATP activity is augmented in
the Bad genetic models, the near complete reversal of the
seizure resistance in Bad null mice with genetic ablation of the
Kir6.2 subunit of the KATP channel provides strong genetic
evidence for the BAD-KATP axis in modulation of seizure suscep-
tibility. Although the genetic data underscore the KATP channel as
a mechanistic component of BAD’s effect in this setting, they do
not rule out contribution from additional consequences of
a glucose-to-ketone-body metabolic shift.
Our findings reveal BAD as a novel molecular player in the
metabolic control of neuronal excitation that imparts robust
changes in susceptibility to both behavioral and electrographic
seizures. BAD’s capacity to modulate the neural choice of
carbon substrate and energy metabolism in the brain, indepen-
dent of dietary manipulation, makes it an attractive candidate
for metabolic manipulation of seizure responses. Small mole-
cules modeled after BAD variants that promote ketone body
catabolism over glucose metabolism may help uncover new
therapeutic targets to treat epileptic disorders.
EXPERIMENTAL PROCEDURES
Animals
Bad/ and BadS155A knockin mice have been previously described (Danial
et al., 2008). Bad genetic models used in this study were bred into the
C57BL/6J genetic background for at least 14 generations and were validated
by genome scanning to be 99.9% congenic with C57BL/6J. Bid/, Bim F/F,
and Kir6.2/, mice have been previously described (Miki et al., 1998; Takeu-
chi et al., 2005; Yin et al., 1999). Nestin-CRE mice were purchased from Jack-
son Laboratory (Bar Harbor, ME, USA). Mice received a standard chow diet
and were housed in a barrier facility with 12 hr light and dark cycles. All animal
procedures were approved by the Institutional Animal Care and Use
Committee of Dana-Farber Cancer Institute and Harvard Medical School.
Cohorts of 8- to 10-week-old male mice were used in all in vivo studies.
Kainic Acid Treatment and Monitoring of Behavioral Seizures
Kainic acid (KA; Tocris Bioscience, MO, USA) was dissolved in saline (Sigma-
Aldrich, St. Louis, MO, USA) and injected intraperitoneally (i.p.) at a dose of
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Metabolic Control by BAD Reduces Seizures via KATP30 mg/kg of body weight. Behavioral seizures in mice were scored every 5 min
for up to 4 hr in accordance with a modified version of the Racine scale as
previously described (Ferraro et al., 1997). Briefly, the modified Racine scale
includes four stages:
Stage 1. Hypoactivity: rigidity, immobility, or crawling, fixed gaze, and
postural abnormalities, including hunched posture.
Stage 2. Partial clonus: behavioral seizure activity affecting mostly the
head (grimacing, twitching, and head nodding) and/or forelimbs(s)
(‘‘paddling’’). Rigidity.
Stage 3. Generalized clonus: loss of upright posture, whole body clonus,
rearing, wild running and jumping, and autonomic signs. Fore- and
hindlimb extension.
Stage 4. Status epilepticus: severe clonic-tonic convulsions. Complete
loss of balance and control.
Seizure severity was scored by an investigator blind to the genotype. In
addition to recording raw seizure scores, seizure severity was determined by
integrating individual scores per mouse over the duration of the experiment
using the following formula:
Seizure Severity=
X
ðall scores of a given mouseÞ=time of experiment:
All scores for a single mouse were added and then divided by the total time
of the experiment for each animal. Themean of the seizure severity values from
wild-type mice was assigned a value of ‘‘100.’’ This value was then used to
normalize the severity of the other tested genotypes within the same scale.
This formula provided better accounting for seizure severity in mice that died
during the experiment.
Pentylenetetrazole Treatment and Monitoring of Behavioral
Seizures
Mice were injected subcutaneously (s.c.) with pentylenetetrazole (PTZ; Sigma-
Aldrich) dissolved in saline at a final dose of 80 mg/kg of body weight as previ-
ously described (Ferraro et al., 1999). Behavioral seizures were scored every
2.5 min up to 80 min in accordance with a modified version of the Racine scale
as detailed previously.
Electroencephalographic Recording
Mice were anesthetized with a mixture of ketamine/xylazine at a dose of 120
and 12 mg/kg of body weight, respectively. Headmounts for EEG recordings
(8200 Series, 3 channel-2 EEG/1 EMG for mice, Pinnacle Technology, Inc.,
KS, USA) were then placed by stereotactic surgery per the manufacturer’s
instructions. Mice were allowed to recover for 5–7 days. After recovery,
a Pinnacle preamplifier was plugged in the headmount, and the mouse was
then placed in an open plexiglas recording cage with wires connected via
a swivel to the digitizer. Data were acquired using the PAL 8200 software
(Pinnacle Technology, Inc.) at a sample rate of 400 Hz.
EEG data were analyzed in MATLAB using the BIOSIG-toolbox (http://
biosig.sf.net) and specially written browsing and analysis software. In addi-
tion to displaying the raw EEG and EMG traces, power in the 20–70 Hz
band was calculated using a fifth-order Butterworth bandpass filter (Lehm-
kuhle et al., 2009) and measured relative to the baseline period to help
identify onset and offset of high-energy spiking. EEGs were scored by an
investigator blind to the genotype, and the fraction of time spent in a high-
energy spiking state was determined for a 30 min period beginning 3 min after
KA injection.
Primary Cultures of Neurons and Astrocytes
Primary cortical neurons were cultured in accordance with an established
protocol with some modifications (Banker and Goslin, 1998). Seventeen-
day-old embryos were dissected in prechilled Hank’s buffered salt solution
(HBSS). After removal of the meninges, striatum, and hippocampus, the intact
cortices were washed in Ca2+ and Mg2+-free HBSS, cut into small pieces and
incubated in a Ca2+ and Mg2+-free HBSS solution containing 0.25% trypsin
(Sigma-Aldrich) and 1 mg/ml DNaseI (Roche Diagnostics, Indianapolis, IN,
USA) for 15 min at 37C with gentle shaking every 3–4 min. The dissociatedcells were then resuspended and plated inminimum essential medium supple-
mented with 0.6% glucose and 10% horse serum (Invitrogen, Carlsbad, CA,
USA). The medium was changed after 4 hr to Neurobasal culture medium
supplemented with B-27, 2 mM GlutaMaxI (all from Invitrogen), and a mix of
penicillin and streptomycin (100 U/ml and 100 mg/ml, respectively). The cells
were plated at 3 3 105 cells/cm2 on poly-L-lysine precoated plates and fed
every 3 days by replacing one-third of the medium with fresh media. Cells
were cultured 5–6 days prior to experiments.
Primary cortical astrocytes were obtained from 1-day-old newborn mouse
pups and processed as above. The cells were seeded on poly-L-lysine-coated
plates in a mixture of Dulbecco’s modified Eagle’s medium (DMEM) + HAMs
F-12 nutrient mixture (1:1) supplemented with 10% fetal bovine serum (FBS;
Invitrogen), 2 mM GlutaMaxI, and a mix of penicillin and streptomycin
(100 U/ml and 100 mg/ml, respectively) and cultured for 2–3 weeks but no
more than two passages. This ensured homogeneity of the primary cultures
prior to mitochondrial respirometry assays.
Assessment of Oxygen Consumption Rate
Real-time measurement of mitochondrial oxygen consumption rate (OCR)
and data processing were carried out using the XF24 extracellular flux
analyzer instrument and the AKOS algorithm built in the XF24 v1.7.0.74
software (Seahorse Bioscience, Inc., Billerica, MA, USA; Wu et al., 2007).
Primary neurons were seeded on poly-L-lysine-coated XF24 V7 plates
at 1 3 105 cells/well and incubated for 5–6 days before OCR measure-
ments. Primary astrocytes were seeded on poly-L-lysine-coated XF24 V7
plates at 4 3 104 cells/well and allowed to recover overnight. On the day
of the experiment, the cells were rinsed once in DMEM without sodium
bicarbonate (Sigma-Aldrich) and preincubated for 1 hr in sodium bicar-
bonate-free DMEM supplemented with the carbon substrate to be tested
(10 mM D-glucose, 5 mM b-D-hydroxybutyrate, 5 mM L-lactate, or 5 mM
L-glutamine). For neurons, the media was additionally supplemented with
B-27.
After baseline measurements, maximal mitochondrial maximal respiration
(MR) in response to a given substrate was determined following the addition
of the uncoupler carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(FCCP, Sigma-Aldrich) at 1 and 0.5 mM final concentration to neurons and
astrocytes, respectively. OCR was then recorded until it reached a plateau.
The fraction of OCR that is due to mitochondrial respiration was determined
by subsequent addition of the mitochondrial complex I inhibitor rotenone
(Sigma-Aldrich) at 1 mM.MRwas derived from the difference betweenmaximal
respiratory rate induced by FCCP and the lowest respiratory rate after rote-
none treatment.
Hippocampal Slice Preparation for Patch-Clamp Recordings
Acute hippocampal slices 400 mm thick were cut in the transverse plane from
the brains of 12- to 18-day-old mice, using a vibrating tissue slicer (Vibratome,
St. Louis, MO, USA). Mice were anesthetized by isoflurane inhalation and
decapitated into an ice-cold slurry containing the following (in mM): 87 NaCl,
25 NaHCO3, 25 D-glucose, 75 sucrose, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2,
and 7 MgCl2 (osmolality 340 mmol/kg; pH 7.4 with NaOH). Slices were incu-
bated at 37C for 20 min in the slicing solution and then for 40 min in recording
solution and then stored at room temperature for 0–3 hr before use. During
recording, ACSF was delivered to the bath using a peristaltic pump at a flow
rate of 1 ml/min. All ACSF solutions for whole-cell and single-channel record-
ings contained the following (in mM): 120 NaCl, 26 NaHCO3, 10 D-glucose,
2.5 KCl, 2 CaCl2, 1.25 NaH2PO4, and 1 MgCl2 (osmolality 300 mmol/kg;
pH 7.4). In addition, all recording solutions contained 100 mM picrotoxin and
1 mM kynurenic acid to block fast synaptic transmission. All bath solutions
were bubbled continuously with 95% O2 and 5% CO2. All chemicals were
purchased from Sigma-Aldrich.
Patch-Clamp Recordings
Cell-attached patch recordings from individual dentate granule neurons iden-
tified under infrared differential interference contrast (IR-DIC) visual guidance
were made in voltage-clamp mode following establishment of high-resistance
(multi-GU) seals. Data were collected with a HEKA EPC 10 patch-clamp ampli-
fier (HEKA Instruments Inc., Bellmore, NY, USA). Macroscopic and single-Neuron 74, 719–730, May 24, 2012 ª2012 Elsevier Inc. 727
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v2x43 software (HEKA Instruments Inc.) was used for amplifier control and
data acquisition. All recordings were obtained at room temperature. Patch
pipettes were pulled from borosilicate glass (VWR Scientific or Dagan LG16
for macroscopic or single-channel current recordings, respectively) using
a Sutter Instruments P-97 puller. Pipette tips were fire polished to resistances
of 2–3 MU when filled with recording solutions.
For cell-attached recordings, the pipette solution contained (in mM): 140
potassium methanesulfonate (KMeS), 10 HEPES, 2 CaCl2, and 10 TEA-Cl, 2
CsCl, 1 4-aminopyridine (4-AP), 100 nM charybdotoxin (in 0.001% BSA;
Alomone Labs, Jerusalem, Israel), and 100 nM apamin (including 40 mM acetic
acid; EMDMillipore, Billerica, MA, USA) to block non-KATP potassium channels
(osmolality 310 mmol/kg; pH to 7.4 with KOH). Peptide blockers were stored
as stocks at 20C and diluted prior to recording.
For whole-cell recordings, the pipette solution contained (in mM):
140 KMeS, 10 NaCl, 10 HEPES, 1 MgCl2, and 0.1 EGTA (osmolality
295 mmol/kg; pH 7.4), supplemented with 0.3 mM Na3GTP and either 0.3 or
4 mMMgATP. A voltage ramp protocol was used to measure input resistance
and slope conductance: from the 90 mV holding potential followed two
100 ms steps first to 100 mV then to 120 mV before initiation of a 1 s
ramp from 120 to 65 mV. The prepulses were used to calculate the cell’s
input resistance. Voltage ramps were applied every 10 s and fitted with
a straight line from 120 to 80 mV to provide a running assessment of
whole-cell slope conductance.
Tolbutamide was diluted in ACSF from a 200 mM stock solution in ethanol.
Ethanol as a vehicle control was added to ACSF at 0.1%. All chemicals are
from Sigma-Aldrich, unless otherwise noted.
Patch-Clamp Data Analysis
Data and statistical analysis were performed with Patchmaster v2x43 (HEKA
Instruments Inc.) and Origin 8 (OriginLab, Northampton, MA, USA). Single-
channel analysis was performed using QuB (http://www.qub.buffalo.edu).
Open and closed levels for channel activity were detected using a 50%
threshold criterion. Raw data sets featuring excessive baseline shift, sufficient
high- or low-frequency noise to preclude effective idealization of channel
openings, or too few data traces (<3 min of recording) were discarded without
idealization or further analysis. The number of independent experiments
(n, Figure 5) corresponds to the number of patches or whole-cell experiments
each from a different hippocampal slice. In all cases, each experimental condi-
tion was tested in slices from at least three different animals.
Statistical Analysis
In all cases, mean ± SEM is presented. The number of independent experi-
ments is indicated in the figure or figure legend in each case. Statistical signif-
icance was determined using two-tailed Student’s t test.
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